Semaglutide & NAION Risk: Ozempic & Wegovy Concerns
- Recent research and alerts from health agencies are highlighting a potential link between the popular weight-loss medications semaglutide – sold under brand names Ozempic, Rybelsus and Wegovy –...
- NAION is a condition that affects the optic nerve, which connects the eye to the brain.
- NAION is the second most common optic neuropathy after glaucoma and a leading cause of non-traumatic vision loss in adults.
Recent research and alerts from health agencies are highlighting a potential link between the popular weight-loss medications semaglutide – sold under brand names Ozempic, Rybelsus and Wegovy – and a rare eye condition that can cause sudden vision loss. While the risk appears to be very low, healthcare professionals and patients should be aware of the potential for non-arteritic anterior ischemic optic neuropathy (NAION).
What is NAION?
NAION is a condition that affects the optic nerve, which connects the eye to the brain. It occurs when blood flow to the optic nerve is disrupted, leading to damage. This damage typically results in sudden, painless vision loss in one eye, although it can occur in both. The vision loss is often irreversible, and currently, there is no proven effective treatment.
NAION is the second most common optic neuropathy after glaucoma and a leading cause of non-traumatic vision loss in adults. It presents as a sudden decrease in vision, often accompanied by swelling of the optic disc, the area where the optic nerve enters the eye.
The Emerging Connection to Semaglutide
The concerns surrounding semaglutide and NAION began to surface with reports of patients experiencing vision loss after starting the medication. Several studies have investigated this potential association. A study published in JAMA Ophthalmology in July 2024, found that individuals with diabetes prescribed semaglutide were more than four times more likely to be diagnosed with NAION compared to those with diabetes who did not take the drug. For those prescribed semaglutide who were overweight or obese, the risk increased to more than seven times higher than similar patients not taking the medication.
The European Medicines Agency (EMA) has reviewed available data, including clinical trials and post-marketing surveillance, and concluded that NAION is a very rare side effect of semaglutide, potentially affecting up to 1 in 10,000 users. The EMA has recommended updating the product information for semaglutide medications to include NAION as a potential side effect.
The World Health Organization (WHO) has also issued a safety alert, advising healthcare professionals and regulatory authorities about the risk. The WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) has recommended revising the Risk Management Plan for semaglutide to include NAION as a potential risk and to consider any additional pharmacovigilance activities that may be needed.
What Does This Mean for Patients?
It’s important to emphasize that NAION is a rare condition, and the absolute risk associated with semaglutide remains low. However, patients taking Ozempic, Rybelsus, or Wegovy should be vigilant for any changes in their vision.
According to the WHO and EMA, if a patient experiences a sudden loss of vision or rapidly worsening eyesight while taking semaglutide, they should contact their doctor immediately. If NAION is confirmed, treatment with semaglutide should be stopped.
Joseph Rizzo, MD, an ophthalmologist at Mass General Brigham, stresses that patients should not discontinue their medications without consulting their physician. To be perfectly clear, I would not take my findings and use them to recommend that patients stop taking their medications,”
Dr. Rizzo stated. Our finding was really the first possible significant negative finding with these drugs.
Understanding Semaglutide and its Uses
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA). It’s an active ingredient in medications used to treat type 2 diabetes, and obesity. These medications work by mimicking a natural hormone that helps regulate blood sugar and appetite, leading to weight loss in some individuals.
Ongoing Monitoring and Research
Health authorities are continuing to monitor the situation and gather more data on the potential link between semaglutide and NAION. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) conducted a thorough review of all available data, including non-clinical studies, clinical trials, post-marketing surveillance, and medical literature. This ongoing monitoring is crucial to better understand the risk and to provide appropriate guidance to healthcare professionals and patients.
The widespread use of semaglutide globally underscores the importance of this safety alert. While the benefits of these medications for managing diabetes and obesity are significant, it’s essential to be aware of potential risks and to seek prompt medical attention if any vision changes occur.
, healthcare providers are encouraged to discuss the potential risk of NAION with patients considering or currently taking semaglutide. Open communication between patients and their doctors is key to ensuring informed decision-making and optimal patient care.